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Cellular senescence is a homeostatic biological process characterized by a permanent
state of cell cycle arrest that can contribute to the decline of the regenerative
potential and function of tissues. The increased presence of senescent cells in
different neurodegenerative diseases suggests the contribution of senescence in the
pathophysiology of these disorders. Although several factors can induce senescence,
DNA damage, oxidative stress, neuroinflammation, and altered proteostasis have
been shown to play a role in its onset. Oxidative stress contributes to accelerated
aging and cognitive dysfunction stages affecting neurogenesis, neuronal differentiation,
connectivity, and survival. During later life stages, it is implicated in the progression of
cognitive decline, synapse loss, and neuronal degeneration. Also, neuroinflammation
exacerbates oxidative stress, synaptic dysfunction, and neuronal death through the
harmful effects of pro-inflammatory cytokines on cell proliferation and maturation. Both
oxidative stress and neuroinflammation can induce DNA damage and alterations in
DNA repair that, in turn, can exacerbate them. Another important feature associated
with senescence is altered proteostasis. Because of the disruption in the function
and balance of the proteome, senescence can modify the proper synthesis, folding,
quality control, and degradation rate of proteins producing, in some diseases, misfolded
proteins or aggregation of abnormal proteins. There is an extensive body of literature
that associates cellular senescence with several neurodegenerative disorders including
Alzheimer’s disease (AD), Down syndrome (DS), and Parkinson’s disease (PD). This
review summarizes the evidence of the shared neuropathological events in these
neurodegenerative diseases and the implication of cellular senescence in their onset
or aggravation. Understanding the role that cellular senescence plays in them could help
to develop new therapeutic strategies.
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INTRODUCTION
Cellular senescence, a homeostatic process that reduces proliferation and helps to prevent the
propagation of damaged cells (Vicencio et al., 2008; Coppé et al., 2010; Faragher et al., 2017; Yanagi
et al., 2017), has been proposed to be a type of cell differentiation (Stein et al., 1991). Among its
most relevant biological functions are the counteraction of uncontrolled cell proliferation, which
avoids the formation of tumors, and the facilitation of the elimination of cells that are damaged or
that are no longer necessary (Kültz, 2005). Cellular senescence has an essential physiological role
during development (Muñoz-Espín and Serrano, 2014; Barbouti et al., 2019).
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According to its duration and characteristics, senescence has
been categorized into acute or chronic senescence (van Deursen,
2014). Acute senescence is implicated in normal biological
processes during embryonic development or tissue repair. While,
chronic senescence, induced by prolonged exposure to stress
(Salama et al., 2014; van Deursen, 2014; Childs et al., 2015;
Velarde and Menon, 2016; Watanabe et al., 2017; Ogrodnik et al.,
2019), produces cellular and tissue alterations. Although both
types of senescent cells display similar characteristics in vitro
and in vivo, they are triggered by different stimuli and have
differential consequences on the tissue.
Chronic cellular senescence contributes to functional
alterations associated with aging and neurodegenerative
diseases (Howcroft et al., 2013); the number of cells with this
phenotype increases with healthy aging (Herbig et al., 2004;
Lawless et al., 2010).
Different categories of chronic senescence have been
identified, including replicative senescence, stress-induced
premature senescence (SIPS), and mitochondrial dysfunction-
associated senescence, among others (Kuilman et al., 2010).
Replicative senescence is the process in which human
fibroblasts cultured in vitro end up displaying the hallmarks of
senescence (a rise in protein p21 levels cell cycle arrest, SA-β-
Gal activation, and morphological alterations; Romanov et al.,
2012; Sanders et al., 2013). Replicative senescence is currently
considered a model of aging (Chen et al., 2007).
Different types of cells of the central nervous system
(CNS) can become senescent, including astrocytes (Pertusa
et al., 2007; Mansour et al., 2008; Salminen et al., 2011),
microglia (Evans et al., 2003; Flanary and Streit, 2004; Flanary
et al., 2007; Bitto et al., 2010), oligodendrocytes (Al-Mashhadi
et al., 2015), neurons (Sedelnikova et al., 2004; Jurk et al.,
2012), and Neural Stem Cells (NSCs; Ferrón et al., 2004;
He et al., 2013; Li et al., 2016). Senescence of these cell
types have been implicated in the etiopathology of several
neurodegenerative diseases (Streit et al., 2004, 2009; Conde
and Streit, 2006; Baker et al., 2011; Bhat et al., 2012; He
et al., 2013; Nasrabady et al., 2018; Ohashi et al., 2018),
including Alzheimer’s disease (AD), Parkinson Disease (PD),
frontotemporal dementia, amyotrophic lateral sclerosis, and
multiple sclerosis (Yurov et al., 2014; Biron-Shental et al., 2015).
This review summarizes the main findings on the role of
cellular senescence in the neurodegenerative diseases AD, Down
syndrome (DS), and PD.
Cellular Senescence: Phenotype,
Triggering Mechanisms and Implication in
Neurodegenerative Diseases
Senescent cells are characterized by:
(i) Permanent cell cycle arrest, due to the blockade to the
entrance to the S phase of the cycle (Stein et al., 1999; Krenning
et al., 2014).
(ii) Senescence-associated secretory phenotype (SASP),
which consists of the synthesis and release of proinflammatory
chemokines, cytokines, growth factors and metalloproteinases
(Coppé et al., 2010; Acosta et al., 2013; Chen et al., 2015)
responsible of neuroinflammatory processes (Coppé et al., 2010;
Freund et al., 2010; Özcan et al., 2016).
During aging and in neurodegenerative diseases, microglial
cells display altered morphology characteristic of senescence
(Flanary and Streit, 2004; Streit et al., 2004; Flanary et al., 2007).
However, it has to be taken into account that increased release
of pro-inflammatory cytokines due to microglia or astroglia
activation is not necessarily related to cellular senescence. During
healthy aging, the brain suffers mild chronic inflammation
(Yankner et al., 2008). There is evidence that this state is caused
by the dysregulation of microglial activation (Sheng et al., 1998;
Frank et al., 2006; von Bernhardi, 2007; Mosher and Wyss-Coray,
2014; von Bernhardi et al., 2015a), which enhances the release
of numerous proinflammatory cytokines, including IL1α, IL-2,
IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-22, IL-23, IL6, IFN-γ
and TNFα (Sheng et al., 1998; Njie et al., 2012; von Bernhardi
et al., 2015b; Minciullo et al., 2016; Ventura et al., 2017; Rea et al.,
2018). Inflammation induces a higher release of proinflammatory
cytokines in old than in young cells (Combrinck et al., 2002;
Cunningham et al., 2005; Sierra et al., 2007; Henry et al., 2009).
In neurodegenerative diseases, neuronal damage also
dysregulates microglia activation and induces an increase in the
release of pro-inflammatory mediators (von Bernhardi, 2007;
López-Otín et al., 2013).
(iii) Altered mitochondrial function and morphology, which
is one of the most important triggers of senescence, mainly
through the induction of oxidative stress, which will alter cellular
signaling and SASP (Takahashi et al., 2005; Passos et al., 2007,
2010; Correia-Melo and Passos, 2015).
High levels of oxidative stress have been demonstrated to
induce cellular senescence during aging (De Haan et al., 1996),
promoting neuronal DNA damage (Chow and Herrup, 2015),
a deregulated DDR (Sedelnikova et al., 2004), an alteration
in the entry and progression of the cell cycle and changes
in cell morphology (Monti et al., 1992), premature replicative
senescence and an accelerated rate of telomere attrition per
cellular replication (von Zglinicki et al., 2000; Serra et al., 2003).
Mitochondria is a major site of production as well as a
target of reactive oxygen species (ROS), and its endogenous
antioxidant pathways are essential to maintain physiological
redox signaling (Brand, 2014). Furthermore, mitochondrial ATP
production is necessary for neural activity. But aging deteriorates
mitochondrial integrity and function leading to reduced
ATP production, to enhanced ROS formation, mutations in
mitochondrial DNA (Richter et al., 1988; Shigenaga et al., 1994),
facilitating neurodegeneration (Dröge and Schipper, 2007).
Finally, mitochondrial ROS can also induce telomere attrition,
and dysfunction (Passos et al., 2007) and mitochondrial
dysfunction can also facilitate senescence by inducing alterations
in the cell metabolism (Ziegler et al., 2015; Liguori et al., 2018).
(iv) Changes in cellular metabolism, partially due to the
altered mitochondrial function, producing an increase in
lysosomal senescence-associated-β-galactosidase (Lee et al., 2006;
Weichhart, 2018), accumulation of lipofuscin in the cytoplasm
(Georgakopoulou et al., 2013; Höhn and Grune, 2013), and a
reduction in fatty acid synthesis (Wu et al., 2017). Due to the
high energy demand, and increased oxidative stress the cells can
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accumulate high levels of DNA damage. This damage increases
during normal aging, when the DNA repair capacity is reduced
(Maynard et al., 2015).
(v) DNA damage that alters chromatin structure and
activates the DNA damage response (DDR) (Nakamura et al.,
2008; Rodier et al., 2011).
Telomere Attrition and Telomere
Dysfunction
During replicative senescence, telomeres, DNA–proteins that
protect chromosome ends from degradation, and inappropriate
recombinations or fusions shorten with every cell division
(Blackburn, 1991; Zakian, 1995; Chan and Blackburn, 2004;
Hockemeyer et al., 2005). Telomere shortening reduces the
protection of the ends of the chromosomes and leaves them
exposed to DNA damage that can be similar to DNA double-
strand break (d’Adda di Fagagna et al., 2003; Takai et al.,
2003; Herbig et al., 2004; Rodier et al., 2009, 2011) that
triggers the DDR. During senescence, the increase in DDR
leaves these cells unable to perform DNA repair (Galbiati
et al., 2017). Under these circumstances, the cell stops dividing
(Harley et al., 1990; Harley, 1991; de Lange, 2002; d’Adda di
Fagagna et al., 2003) leading to the cell cycle arrest characteristic
of senescence.
Telomere shortening has been proposed to be a major
mechanism in aging, and age-related pathology and a marker
of cellular senescence (Greider and Blackburn, 1987; Olovnikov,
1996; Bernatdotte et al., 2016). The role of telomere attrition in
aging and its correlation with senescence has been demonstrated
in studies in primates, mice and humans (Blasco et al., 1997; Lee
et al., 1998; Herbig et al., 2006; Hewitt et al., 2012; Kong et al.,
2013; López-Otín et al., 2013; Birch et al., 2015).
Besides cellular replication, several stimuli can affect
telomeres. There is evidence that mitochondrial dysfunction
induces telomere damage, and that telomere damage can produce
mitochondrial alterations (Zheng et al., 2019). Besides, oxidative
stress accelerates telomere damage producing senescence (von
Zglinicki et al., 2000; von Zglinicki, 2002; Saretzki et al., 2003;
Serra et al., 2003), and the intracellular oxidative stress of a
cell correlates with telomere attrition and with its replicative
potential (Richter and von Zglinicki, 2007).
Although, as mentioned above, many studies have shown a
relation between telomere attrition, senescence and aging (Harley
et al., 1990; Allsopp et al., 1992; Hao et al., 2005; Heidinger et al.,
2012; Kaul et al., 2012; Reichert et al., 2013), telomere length
does not always correlate with senescence (Karlseder et al., 2002;
Stewart et al., 2003).
Several reports failed to associate telomere length and
mortality risk in elder humans (Bischoff et al., 2006; Li et al.,
2015). Also, some studies have demonstrated that telomere
dysfunction is not dependent on its length. In mice, and baboons
longer telomeres with DNA-damage have been associated with
aging (Fumagalli et al., 2012; Hewitt et al., 2012; Jurk et al., 2014).
Finally, as previously mentioned, telomere dysfunction is not
only related to senescence in healthy aging but it is also found in
patients with dementia (Kota et al., 2015), AD (Cai et al., 2013),
and PD (Maeda et al., 2012).
Non-telomeric DNA Damage
Genomic Instability and DNA Damage and Repair
The continuous activation of DDR produces senescence in
neurons (Fielder et al., 2017). DNA damage induces senescence,
enhanced oxidative stress and an associated increase in
β-galactosidase activity in neurons of old mice (Jurk et al., 2012).
Because the efficiency of DNA repair decreases with age, and
more complex, and less efficient DNA repair mechanisms are
used, the increased DNA damage can lead to neurodegeneration
(Vaidya et al., 2014).
(vi) Epigenetic modifications. Epigenomic changes in
senescent cells include an imbalance in repressive and active
histone marks, heterochromatic alterations including formation
of senescence-associated heterochromatic foci (SAHF), histone
variants, altered nucleosomal composition, alterations in DNA
methylation pattern, alterations in nuclear lamina-chromatin
interactions and on 3D genome organization that contributes to
cellular dysfunction (Yang and Sen, 2018; Wagner, 2019). Micro-
RNAs, also participate in the regulation of cellular senescence
(Komseli et al., 2018); resistance to apoptotic death, controlled
by the p53 and p21 stress response pathway (Tang et al., 2006).
Epigenetic modification such as histone modifications and
specific DNA methylation changes, including alterations in the
activity of methylation enzymes (Vanyushin et al., 1973), occur
during aging and are associated with the neuropathology and
the progression of various neurodegenerative diseases (Berson
et al., 2018; Prasad and Jho, 2019; Wagner, 2019). During aging,
these changes in DNA methylation and histone modifications
alter chromatin architecture (Tsurumi and Li, 2012). Aged tissues
also display alterations in the expression of some micro RNAs
(Cencioni et al., 2013).
(vii) Morphological changes. Senescent cells display
changes in the organization of nuclear lamina that modify
nuclear morphology and gene expression (Freund et al., 2012).
Due to cytoskeletal rearrangements, senescent cells display an
increased size, a flat and irregular shape and changes in cell
membrane composition (Ohno-Iwashita et al., 2010; Druelle
et al., 2016; Cormenier et al., 2018).
(viii) Altered proteostasis. Senescence cells display
increased unfolded protein response (UPR) associated
with endoplasmic reticulum (ER) stress, which participates
in the increase in ER size and the changes in the shape and size of
these cells (Ohno-Iwashita et al., 2010; Cormenier et al., 2018).
Proteostasis refers to the balance and correct function of
the proteome and requires proper synthesis, folding, quality
control, and degradation rate of proteins. In eukaryotic cells, it
depends on the accurate regulation of the proteasome, on the
lysosomal system and autophagy, an intracellular degradation
system of damaged proteins (López-Otín et al., 2013). Senescent
cells lose protein homeostasis due to nucleolar dysfunction,
autophagy and lysosomal anomalies and alterations in UPR
indicative of ER stress. Correct proteostasis reduces the secretion
of inflammatory cytokines (Tanaka and Matsuda, 2014), while
its alteration (including protein misfolding aggregation and
deposition) are a hallmark of many neurodegenerative diseases
(see below for PD and AD).
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FIGURE 1 | Image of a granular neuron (NeuN+) of the hippocampus of an aged wildtype mouse showing senescent phenotypes SA-β-Gal expression, and
changes in cell morphology. This figure summarizes the triggering stimuli (in red) and the consequences (in black) of the increase in the number of cells with senescent
phenotypes in neurodegenerative diseases. The black dotted lines represent the positive feedback mechanism that aggravates aging and neurodegeneration.
In summary, some of the factors that trigger senescence
in pathological conditions are oxidative SIPS (Hernandez-
Segura et al., 2018), mitochondrial dysfunction (Wiley et al.,
2017), DNA-damage (Dörr et al., 2013), telomere attrition
or dysfunction (Hayflick and Moorhead, 1961), aberrant
gene activation (Gorgoulis and Halazonetis, 2010), epigenetic
modifications (Yang and Sen, 2018; Wagner, 2019), and impaired
autophagy (Kang et al., 2011), although other stressors can also
induce senescence (Figure 1).
Finally, as previously mentioned, there is evidence that
cellular senescence contributes to the pathogenesis of different
neurodegenerative diseases through various mechanisms
(Figure 1) including:
(i) The promotion of chronic inflammation: (Coppé et al.,
2010). Thus, neuroinflammation is not only a trigger but also a
result of senescence that can perpetuate the damage to the cell or
neighboring cells (Nelson et al., 2012; Acosta et al., 2013; Ribezzo
et al., 2016).
(ii) The promotion of oxidative stress and mitochondrial
dysfunction. There is a positive feedback mechanism between
senescence, oxidative stress, and mitochondrial dysfunction
(Pole et al., 2016; Figure 1).
(iii) The reduction of the regenerative capacities of the nervous
system: adult neurogenesis has been demonstrated in rodents
(Kriegstein and Alvarez-Buylla, 2009; Ming and Song, 2011) and
humans (Cipriani et al., 2018). Importantly, it has been recently
demonstrated that neurogenesis is reduced in aged individuals
and AD patients (Moreno-Jiménez et al., 2019). Due to the cell
cycle arrest associated with cellular senescence, the reduced
regenerative capacities of the brain (i.e., neurogenesis), would
facilitate neurodegeneration.
(iv) Loss of function: finally, cell-cycle arrest and other
alterations associated with cellular senescence alter the function
of neurons and different CNS cell types (Purcell et al., 2014).
Aging increases the number of senescent cells (Rodier and
Campisi, 2011) and the loss of neurons (De Stefano et al., 2016),
compromising brain function and triggering or aggravating
a neurodegenerative disease. Because senescent cells cannot
maintain tissue function or repair its damage, if this state is
maintained chronically, cellular aging and degenerative diseases
would be aggravated.
In this review, we summarize the data that demonstrate the
role of cellular senescence in the neurodegenerative diseases
AD, DS, and PD (Table 1). Despite the differences in pathology
among these three diseases, they are characterized by senescence
and progressive loss of neurons leading to functional alterations
(Nussbaum and Ellis, 2003).
CELLULAR SENESCENCE IN
ALZHEIMER’S DISEASE
AD is a chronic neurodegenerative disease that accounts
for 60–70% of cases of dementia. The main pathological
hallmarks of AD are dementia and cognitive impairment,
amyloid plaques, neurofibrillary tangles (NFTs) of
hyperphosphorylated tau proteins, and loss of neurons and














TABLE 1 | Summary of senescent phenotypes in normal aging, Alzheimer’s disease (AD), Down syndrome (DS), Parkinson Disease (PD).
Senescence phenotypes Normal aging AD DS PD
Cell cycle arrest Cell cycle arrest (alterations in cell and
tissue functions).
Cell cycle prolongation and re-entry. Cell cycle arrest and elongation. Cell cycle arrest (alterations in the
expression of several genes implicated in
the cell cycle).
SASP Brain mild chronic inflammation, changes in
microglia morphology, altered microglia
activation, enhanced release of
proinflammatory mediators.
Microglia overactivation, enhanced release
of proinflammatory cytokines and other




release of proinflammatory cytokines from
early late stages, as the person ages this is
enhanced and aggravates AD
neuropathology.
Activation of microglia and
pro-inflammatory mediators release that
has a role in the dopaminergic loss.
Oxidative stress and
mitochondrial dysfunction
Increased ROS and mtROS.
Altered mitochondrial integrity and function
that compromises cell metabolism (reduces
ATP) and induces damage DNA.
Increased ROS and altered mitochondrial
structure and function that produces cellular
changes associated with senescence.
Increased ROS and mtROS from embryonic
stages.
Altered mitochondrial structure and function
that compromises cell metabolism (reduces
ATP production). As the person ages,
oxidative stress is enhanced and
aggravates AD neuropathology. Oxidative
stress-induced damage of DNA, lipids, and
proteins.
Increased ROS and mtROS.
Altered mitochondrial structure and
function.
Mutation of genes associated with
pathways of mitochondrial dysfunction.





Shorter telomeres correlate with the degree
of dementia in DS individuals with AD.
Contradictory results regarding telomere
length.
Non-telomeric DNA
damage and DNA repair
mechanism
Increased DNA damage accumulation and
alteration in DDR.
Increased DNA damage and alterations in
DDR.
Oxidative stress and other stressors
enhance DNA damage accumulation.
Overexpression of the USP16 gene and the
reduced DNA POLb alter DNA repair
mechanisms and chromatin remodeling.
Genomic instability.
Genetic instability due to gene mutations,
altered gene expression or regulation
leading to cell cycle alterations.
Impaired DNA repair mechanisms that
increase the duration of cell cycle.
Epigenetic modifications Alterations in histones, DNA methylation
pattern, chromatin architecture, and micro
RNAs expression.
Aberrant phosphorylation of histones,
changes in DNA methylation of AD critical
genes.
Mislocated chromatin organizing proteins
and epigenetic regulators.
Histone modifications, DNA
hypermethylation, alteration in small
non-coding RNAs implicated in premature
aging and cognitive defects.
Changes in DNA methylation,
posttranscriptional modification of
histones.
Morphological changes Increased size, flat and irregular shape,
changes in membrane composition.
Increased size, flat and irregular shape,
changes in membrane composition.
Increased size, flat and irregular shape,
changes in membrane composition.
Increased size, flat and irregular shape,



















































































































































































































































































































































































































































































































synapses (Selkoe and Hardy, 2016). However, there is increasing
evidence that some pathological events that appear years earlier
than the former have a prominent role in the development of
amyloid plaques and NFTs. These events include increased
oxidative stress, neuroinflammation, and cellular senescence due
to DNA damage and altered proteostasis. Numerous reports
have demonstrated their role in the increase in Aβ burden,
tau hyperphosphorylation, neuronal death and an accelerated
cognitive decline (Hardy and Higgins, 1992; Gitter et al., 1995;
Chong, 1997; Weldon et al., 1998; Eikelenboom et al., 2006;
Hardy, 2006; Sipos et al., 2007; Wilcock, 2012).
Cellular senescence has been demonstrated to play an
important role in the onset and aggravation of AD (Bhat
et al., 2012; Boccardi et al., 2015). Increased senescence is
found in different cell types of AD brains, including astrocytes,
microglia, and neurons as demonstrated by their enhanced SA-
β-gal expression (He et al., 2013), p53 expression, a mediator of
cellular senescence (Arendt et al., 1996; McShea et al., 1997; Luth
et al., 2000; Yates et al., 2015), an increase in the release of SASP
components (Erusalimsky, 2009), DNA damage (Myung et al.,
2008), telomere attrition or damage (Flanary and Streit, 2004),
and senescence-like morphological changes (Streit et al., 2004).
Increased levels of senescent cells with higher SA-β-gal and
p53 levels are also found and in plasma samples from AD patients
and mouse models of AD (de la Monte et al., 1997; Tiribuzi et al.,
2011; Magini et al., 2015; Caldeira et al., 2017).
Several studies have demonstrated an association between
senescence and AD neurodegeneration. In cultured neurons, the
expression of several senescent-associated genes was upregulated
after the exposure to Aβ (Wei et al., 2016). These results were
also confirmed in vivo, using the 5× FAD mouse model of
AD that displays progressive Aβ deposition. After 7 months
of age, this model shows the upregulation of some essential
senescent—related genes in the hippocampus (Wei et al., 2016).
Besides, a murine model that overexpresses human tau and
develop NFT deposition also shows increased expression of
several senescent—associated genes in the hippocampus and
cortex (Bussian et al., 2018).
Besides, the administration of Aβ oligomers to
oligodendrocyte progenitor cells can also induce senescence
(Zhang et al., 2019) and in murine neural stem cells,
Aβ42 peptides increase the number of SA-β-Gal positive
cells (He et al., 2013). The removal of senescent cells in mice
reduces Aβ accumulation and enhances their cognitive abilities
(Zhang et al., 2019). Besides, hyperphosphorylation of tau can
induce senescence in glial cells (Musi et al., 2018).
The fact that many of the early alterations found in AD
(i.e., neuroinflammation, oxidative stress, DNA damage and
changes in DNA repair and altered proteostasis) trigger or are
associated with cellular senescence, has led to the suggestion that
this process has a crucial role in the etiopathology of AD.
Neuroinflammation
The brains of AD patients and of mouse models of AD have
higher levels of inflammation due to microglia activation that
produces pro-inflammatory cytokines and other SASP mediators
(Streit et al., 2004; Hickman et al., 2008; Rawji et al., 2016;
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Olivieri et al., 2018). Neuroinflammation in the brain of AD
patients is influenced by many SASPs mediators (Bauer et al.,
1991; Huell et al., 1995; Kiecolt-Glaser et al., 2003) that have a
prominent role in the onset of senescence (Flanary and Streit,
2004; Flanary et al., 2007). IL-6, a proinflammatory cytokine, is
upregulated in the aged brain and AD (Bauer et al., 1991; Huell
et al., 1995; Kiecolt-Glaser et al., 2003) and its overexpression has
been shown to induce neurodegeneration (Campbell et al., 1993).
The brains and lymphocytes of AD patients and AD mouse
models also present increased activity of the SASP regulator
p38MAPK (Sun et al., 2003). This enhanced p38MAPK activity
upregulates the levels of the pro-inflammatory cytokines IL-6,
IL-1, TGF-β and TNF-α levels in AD brains (Bauer et al., 1991;
Huell et al., 1995; Freund et al., 2012; Lai et al., 2017; Rea
et al., 2018), CSF and serum (Wood et al., 1993; Cacabelos
et al., 1994; Blum-Degen et al., 1995; Luterman et al., 2000;
Swardfager et al., 2010; Tarkowski et al., 2003; Gezen-Ak et al.,
2013; Dursun et al., 2015). AD brains also present increased
levels of other SASPs mediators: the metalloproteinases MMP-
1, MMP-3, and MMP-10 (Leake et al., 2000; Yoshiyama et al.,
2000; Bjerke et al., 2011; Horstmann et al., 2018). The fact that
SASP meditators have a prominent role in the onset of senescence
(Flanary and Streit, 2004; Flanary et al., 2007), provide support
for the relationship between neuroinflammation and senescence
in AD neuropathology.
Neuroinflammation aggravates AD (Guerreiro et al., 2013)
mainly because it increases APP and Aβ expression in this
disease. Pro-inflammatory cytokines induce the formation of
Aβ oligomers, the phosphorylation of tau, and ROS production
(Sastre et al., 2003; Blurton-Jones and Laferla, 2006; Steele et al.,
2007). In turn, Aβ peptides and APP activate glial cells (Dickson
et al., 1993; Barger and Harmon, 1997), produce an enhanced
release of pro-inflammatory mediators such as IL-1 and IFNγ in
the brains of AD patients (Ho et al., 2005; Meager, 2004, 2005).
Under these circumstances, in AD, microglia internalize less Aβ
(Floden and Combs, 2011; Njie et al., 2012) and are less able to
process it (Nixon et al., 2001; Hickman et al., 2008; Mawuenyega
et al., 2010). The higher release of pro-inflammatory cytokines
reduces the ability of the cells to remove Aβ and facilitates
its accumulation. Thus, there is a positive feedback between
cytokine release, Aβ, and APP expression, phosphorylated tau
and neurodegeneration (Wilcock and Griffin, 2013).
Oxidative Stress and Mitochondrial
Dysfunction
Oxidative stress is another crucial mechanism that contributes to
accelerating aging and cognitive dysfunction in AD and during
aging (López-Otín et al., 2013). AD patients and mouse models
of AD, present increased oxidative stress and mitochondrial
dysfunction, similar to that observed in senescence. These events
are present in the early stages of AD and precede the major
pathologic hallmarks, such as senile plaques and NFTs (Yates
et al., 2015; Ott et al., 2018).
In AD mitochondrial function and structure are impaired
(Cadonic et al., 2016; Tai et al., 2017), which has a critical role in
the progression of SIPS (Gao et al., 2017). Besides, the enhanced
production of ROS decreases ATP synthesis. Because DNA repair
is a mechanism that requires a high amount of energy, and DNA
is heavily damaged in cells exposed to oxidative stress (Monti
et al., 1992), these cells would need a high amount of energy to
perform DNA repair. Thus, mitochondrial dysfunction reduces
the ability of the cell to repair these alterations.
As mentioned in the ‘‘Introduction’’ section, during aging,
high levels of oxidative stress induce in cells a state of senescence
that displays its main pathological characteristics, including
DNA damage, altered DDR, alterations in the cell cycle and cell
morphology and telomere damage (Monti et al., 1992; De Haan
et al., 1996; von Zglinicki et al., 2000; Serra et al., 2003; Chow and
Herrup, 2015; Kawanishi and Oikawa, 2004; Jennings et al., 2000;
Liu et al., 2003). Thus, a link between oxidative stress and cellular
senescence has been postulated in AD.
Evidence for the relation between oxidative stress and cellular
senescence in AD comes from studies in mouse models of AD
in which the animals were subjected to chronic oxidative stress
(SIPS) and found cellular changes identical to those found in
other types of senescence: i.e., an increase in SA-β-gal expression,
cell cycle arrest and alterations in cellular morphology (Toussaint
et al., 2000; Ma et al., 2014). Besides, fibroblasts from AD patients
produced more ROS, a slowing in the growth rate, an increase
in the expression of p53 and p21 and senescence-like phenotype
(Toussaint et al., 2000; Naderi et al., 2006).
DNA Damage and Repair
As mentioned above, DNA damage and alterations in DNA
repair are two of the main characteristics of cellular senescence
(Sedelnikova et al., 2004) and are associated with aging (Brosh
and Bohr, 2007). In AD, enhanced DNA damage and reduced
DDR has also been demonstrated, and these alterations seem to
accelerate the progression of the disease (Lovell et al., 1999).
Telomere attrition and damage have been proposed to be a
potential contributor in the pathogenesis of several neurological
disorders including AD (Eitan et al., 2014; Boccardi et al., 2015;
Forero et al., 2016). However, there are contradictory reports on
the role of telomeres alterations on AD neuropathology.
Some studies have shown that telomere shortening or
alteration might be implicated in AD pathology (Aβ burden,
hyperphosphorylation of tau and dementia) (Grodstein et al.,
2008; Jenkins et al., 2008; Guan et al., 2012).
In monocytes of AD patients, shorter telomeres were found
(Hochstrasser et al., 2012). Shorter telomere length was also
found in patients with AD than in those with mild cognitive
impairment than in healthy controls (Scarabino et al., 2017).
Moreover, a meta-analysis of 13 studies concluded that there is
evidence that AD patients are more likely to present telomere
attrition (Forero et al., 2016).
However, other studies did not find changes in the length of
the telomeres of patients with AD (Hinterberger et al., 2017).
The telomere length of tissue obtained from the cerebellum
of AD patients did not differ from age-matched controls
(Lukens et al., 2009). In studies that evaluated telomere length
in patients with different types of dementia (Zekry et al.,
2010) or with dementia of AD types, no differences were
found between affected patients and controls (Takata et al.,
2012; Hinterberger et al., 2017). Also, in a mouse model of AD,
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telomere shortening reduces Aβ burden and improves cognition
(Rolyan et al., 2011), although the animals still showed enhanced
DNA damage and neurodegeneration.
Therefore, more studies are necessary to clarify the role of
telomere attrition in AD neuropathology.
Additionally, an association between reduced
lifespan, elevated levels of DNA damage, and a
prolongation of the cell cycle duration have been demonstrated
(Weirich-Schwaiger et al., 1994). In AD there is also evidence
that there are significant alterations of cell cycle re-entry of
post-mitotic neurons (Vincent et al., 1996; Nagy, 2005; Herrup
and Yang, 2007).
During senescence, the accumulated DNA errors alter cellular
functions such as transcription and DNA repair (Hackett et al.,
1981; Cleaver et al., 1983; Mayne, 1984; Friedberg, 1985; Klocker
et al., 1985). These alterations are more evident during aging
(Staiano-Coico et al., 1983; Nette et al., 1984; Dutkowski et al.,
1985; Mayer et al., 1989; Roth et al., 1989). Moreover, in AD, an
enhanced DDR is found in the hippocampus and lymphocytes,
as demonstrated by the presence of elevated levels of the
phosphorylated histone γH2AX (H2A histone family member X)
(Silva et al., 2014; Siddiqui et al., 2018).
In neurodegenerative diseases, epigenetic modifications, such
as alteration in DNA methylation occur early in the disease
process, affect to particular genes and correlate with misfolded
proteins in specific brain regions (Armstrong et al., 2019; Prasad
and Jho, 2019).
AD, PD, and DS among other neurodegenerative diseases
have common aberrant DNA methylation profile that mainly
affects the expression of critical genes involved in various
signaling pathways that are implicated in several pathological
hallmarks such as presence of Aβ plaques, NFT or α-synuclein
inclusions that are present in some of them (Sanchez-Mut et al.,
2016; Armstrong et al., 2019; Prasad and Jho, 2019).
Among the epigenetic alterations found in AD, DNA
methylation and histone modifications show evident
deregulation. It has been demonstrated that in AD brains
changes in DNA methylation affect to a few common gene loci
which play an essential role in the formation of Aβ plaques
(Lord and Cruchaga, 2014; Watson et al., 2016; Qazi et al., 2018;
Armstrong et al., 2019; Esposito and Sherr, 2019; Prasad and Jho,
2019). Among them, of particular interest are the differences
in methylation in different regions of the APP gene promoters
in the brains of humans with AD and these changes have been
associated with neuropathological markers of this disorder
(Bradley-Whitman and Lovell, 2013). Besides, in AD brains
histone modifications have been linked to the reduction in
transcription of genes that are implicated in neuronal physiology
and increased the transcription of genes that are normally
silenced (Berson et al., 2018). The phosphorylated histone
H3 presents an altered localization of the cytoplasm, while the
levels of the acetylated histone H4 are decreased in AD patients
(Kwon et al., 2016).
Also, chromatin organizing proteins and epigenetic regulators
are mislocated in AD, affecting chromatin architecture (Winick-
Ng and Rylett, 2018). Finally, in AD, other epigenetic
modifications such as alterations in chromatin remodelers,
phosphorylation of histones have been found (Esposito and
Sherr, 2019), and might be associated with senescence.
Proteostasis
Altered proteostasis is a phenotypic hallmark of senescent
cells. The integrity of the nucleolar ribosome biogenesis
machinery and the ER, as well as the correct function of the
degradation machinery (ubiquitin-proteasome and lysosomal
pathways), are essential for maintaining proteostasis (Labbadia
and Morimoto, 2015). The perturbation of proteostasis leads
to misfolded protein accumulation and proteotoxic stress
(Hetz and Mollereau, 2014; Hipp et al., 2014), which also
contributes to neurodegeneration. Senescent cells lose protein
homeostasis due to nucleolar dysfunction, autophagy and
lysosomal anomalies and alterations in UPR indicative of
ER stress. The majority of neurodegenerative disorders, present
impairments of degradative compartments such as lysosomes
and autophagosomes.
Protein dysfunction has been associated with numerous
human neurodegenerative diseases such as AD, PD,
amyotrophic lateral sclerosis, spinocerebellar ataxia, and
Huntington’s disease (Yurov et al., 2014). In these diseases,
high levels of different toxic protein aggregates due to a
loss of protein homeostasis have been found. In particular, in
AD, the formation of Aβ plaques (Ow and Dunstan, 2014),
which is directly associated with the expression of SASP-
associated factors (Bhat et al., 2012), and of NFT, composed by
hyperphosphorylated tau protein, increase with the acquisition
of a senescent phenotype and at the same time both induce
senescence (Zare-Shahabadi et al., 2015; Chung et al., 2018;
Mendelsohn and Larrick, 2018).
These alterations have been demonstrated to contribute to the
etiology and progression of AD (Ihara et al., 2012; Nixon, 2013;
Hetz and Mollereau, 2014). In this disorder, the most common
form of protein aggregation, in Aβ plaques (Ow and Dunstan,
2014), which is directly associated with the expression of SASP-
associated factors (Bhat et al., 2012), is one of the primary triggers
and consequences of cellular senescence. The other abnormal
protein found in AD brains is hyperphosphorylated tau in the
form of NFTs, which have been reported to induce senescence
(Mendelsohn and Larrick, 2018).
CELLULAR SENESCENCE IN DOWN
SYNDROME
DS, or trisomy of chromosome 21, is the primary cause
of cognitive disability of genetic origin (Shin et al., 2009).
These cognitive alterations are due to defects in growth
and differentiation of the CNS that appear during early
prenatal stages (Haydar and Reeves, 2012; Lott, 2012). DS is
characterized by premature aging and early appearance (around
the fourth decade of life) of neuropathology identical to the
one found in sporadic AD, including amyloid plaques, NFTs,
neurodegeneration, and synapse loss (Teipel and Hampel, 2006;
Sabbagh et al., 2011; Cenini et al., 2012; Lott, 2012; Wilcock and
Griffin, 2013; Casanova et al., 1985; McGeer et al., 1985). Both,
premature aging and AD pathology are thought to be the leading
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causes of the earlier mortality of this population (Schupf and
Sergievsky, 2002; Zigman and Lott, 2007; Prasher et al., 2008;
Esbensen, 2010).
Neuroinflammation
The DS brain also present neuroinflammatory changes typical
of AD, such as microglial activation and increased release of
pro-inflammatory cytokines (Griffin et al., 1989; Park et al., 2005;
Griffin, 2006; Wilcock and Griffin, 2013). There is compelling
evidence that, in DS, the increased release of cytokines due
to microglia activation, enhances the production of ROS,
aggravates synaptic dysfunction, and neurodegeneration, and
reduces neurogenesis (Town et al., 2005; Fuster-Matanzo et al.,
2013; Llorens-Martín et al., 2014; Lyman et al., 2014; Rosi
et al., 2012). The aggravation produced by neuroinflammation
on neurodegeneration and the reduced neurogenesis (see
Rueda et al., 2012), render DS individuals more susceptible
to neuropathological events that can accelerate the onset of
dementia (Teipel and Hampel, 2006).
Enhanced microglial activation also produces an increased
expression of proinflammatory cytokines in different areas of the
brain of a mouse model of DS (Hunter et al., 2004; Lockrow
et al., 2011; Roberson et al., 2012; Rueda et al., 2018). Reducing
neuroinflammation by administering an antibody against the
pro-inflammatory cytokine IL17A to these mice, reduces cellular
senescence in the hippocampus and cortex of these animals,
improves their cognitive abilities and reduces some of the signs
of neurodegeneration (Rueda et al., 2018). These results suggest a
direct link between cellular senescence, neuroinflammation and
neurodegeneration in DS.
Oxidative Stress and Mitochondrial
Dysfunction
Another crucial mechanism that contributes to accelerating
aging and cognitive dysfunction in DS is oxidative stress. In
this syndrome, it is present from embryonic stages producing a
reduction in neuronal proliferation, differentiation, connectivity,
and survival (Monti et al., 1992; Busciglio and Yankner, 1995;
Perluigi et al., 2011). As the person with DS ages, the levels
of oxidative stress increases, contributing to the progression
of cognitive and neuronal degeneration (Busciglio et al., 2007;
Lockrow et al., 2009; Shichiri et al., 2011; Perluigi and Butterfield,
2012; Rueda et al., 2012; Parisotto et al., 2016). As previously
mentioned, oxidative stress is an essential factor that causes
cellular senescence (Monti et al., 1992; He et al., 2013; Rodríguez-
Sureda et al., 2015).
Furthermore, mitochondrial dysfunction is also present in DS
cells during embryonic life (Perluigi et al., 2011), leading to
profound alterations in energy metabolism due to the reduced
synthesis of ATP synthesis (Valenti et al., 2010). ATP is also
reduced in vitro in DS fibroblasts, which could contribute to
premature cell aging (Rodríguez-Sureda et al., 2015).
In DS, early induction of senescence by aberrant intracellular
oxidant activity and antioxidant defense has been demonstrated
in fibroblasts, skin tissue, lymphocytes (De Haan et al., 1996;
Kalanj-Bognar et al., 2002; Cristofalo et al., 2004; Kimura
et al., 2005; Biron-Shental et al., 2015; Rodríguez-Sureda et al.,
2015) and in the amniotic fluid of women carrying DS fetuses
(Perluigi et al., 2011; Amiel et al., 2013). Thus, senescence is
present in DS from prenatal stages and can be responsible
for different altered phenotypes. But, enhanced senescence is
a prominent phenomenon during all the life stages of a DS
individual and is aggravated with aging and the appearance of
AD neuropathology.
In agreement with these results, it has been demonstrated that
the hippocampus of a mouse model of DS shows higher amounts
of oxidative damage (protein and lipid oxidative damage), Aβ
expression and tau phosphorylation, as well as increased density
of senescent cells in different hippocampal regions (i.e., DG,
CA1, CA3, and hilus; Corrales et al., 2013; Parisotto et al., 2016;
García-Cerro et al., 2017; Rueda et al., 2018). Other authors
have also found the early presence of SA-β-gal activity in both
cultured fibroblasts and skin tissue from DS mice (Contestabile
et al., 2009b). Finally, chronic administration of melatonin,
a potent antioxidant, to this mouse model of DS reduces
hippocampal senescence and oxidative damage, improves the
cognitive abilities of these mice, enhances neurogenesis and
reduces their neurodegenerative phenotype (Corrales et al., 2013,
2014; Parisotto et al., 2016). These results provide support for the
association between oxidative stress and senescence in DS.
DNA Damage and Repair
Hematopoietic stem cells and satellite cells of skeletal myofibers
in the Ts65Dn mouse model of DS accumulate DNA damage and
prematurely develop a senescent phenotype (Adorno et al., 2013;
Wang et al., 2016; Pawlikowski et al., 2018). Furthermore, in this
murine model, the ubiquitin-specific-peptidase 16 (Usp16) gene
is triplicated, leading to the overexpression of the Usp16 enzyme
that controls the ubiquitination state of the histone 2A (Ub-H2A)
and contributes to regulate the DDR chromatin remodeling
and cell cycle progression (Joo et al., 2007). Thus, in these
mice, both the overexpression of the Usp16 gene, which may
affect the DNA damage/repair signaling pathways and the high
levels of brain oxidative stress and neuroinflammation may
produce and excessive accumulation of DNA damage leading
to genomic instability and neurodegeneration or premature
cellular senescence.
In DS, there is also evidence of prenatal accumulation of
DNA damage and of the reduction of the ability to repair DNA
(Agarwal et al., 1970; Raji et al., 1998; Pogribna et al., 2001;
Cabelof et al., 2009; Nižeti ć and Groet, 2012; Di Domenico et al.,
2015). Besides, in response to DNA damage, DNA polymerase b
(POLb), whose function is to participate in base excision repair
(BER) is induced; however, in DS fibroblasts its expression is
reduced, thereby reducing the ability to repair DNA damage.
This reduction is sufficient to induce senescence (Ahmed et al.,
2018; Cabelof et al., 2002, 2003; Cabelof, 2007).
In DS, both alterations in the DNA damage/repair signaling
pathways, and the high levels of brain oxidative stress may
produce and excessive accumulation of DNA damage leading
to genomic instability and neurodegeneration or premature
cellular senescence. Hence, this mechanism might play an
essential role in the onset and aggravation of the AD-associated
cognitive decline.
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DNA repair mechanisms eliminate damages and
elongate cell cycle duration to give the repair enzymes time
to work. However, alterations in DNA repair mechanisms
producing accumulated DNA damage can delay the cell cycle
until mitotic activity ceases, leading to premature senescence
and sometimes cell death. In DS, enhanced DNA damage and
impairment in DNA repair impairs mitosis and delays the cell
cycle leading to senescence. There is evidence of delayed cell
cycle in DS individuals and mouse models of this syndrome
(Contestabile et al., 2007, 2009a).
As mentioned above, telomere attrition is one of the
best-characterized senescence-triggering mechanisms.
Telomeres are shorter in DS amniocytes, and placentas of
fetuses with DS present an increased percentage of trophoblasts
with senescence phenotypes (Sukenik-Halevy et al., 2011; Amiel
et al., 2013; Biron-Shental et al., 2015). For this reason, it has
been suggested that it could be an early biomarker of premature
senescence (Vaziri et al., 1993). Also, a significantly higher
loss of telomere sequences was observed in vitro and in vivo in
lymphocytes from DS individuals (0–45 years old) (Vaziri et al.,
1993; de Arruda Cardoso Smith et al., 2004). Jenkins et al. (2008)
also demonstrated that shorter telomere length correlates with
the degree of dementia and AD-associated neurodegeneration
in DS individuals. These results suggest that senescence can
play an essential role in the aging of the immune system in DS
(Vaziri et al., 1993), leading to the altered microglia function
and neuroinflammation. Thus, in DS, this type of DNA damage
can induce senescence from prenatal stages through the entire
lifespan of the individual.
Epigenetic Modifications
Epigenetic alterations such as DNA and histone modifications
are also found in patients with DS. Among them, DNA
hypermethylation, histone modifications, histone core variants
and changes in small non-coding RNAs are implicated in
several phenotypic characteristics of DS such as memory
impairment, premature aging and neurodevelopmental defects
(Mentis, 2016).
Although some of these alterations are associated with
premature aging in DS, the exact implication of epigenetic
modifications in cellular senescence found in this syndrome
needs to be elucidated.
Proteostasis
Abnormalities in chromosome number disrupt proteostasis
(Oromendia et al., 2012; Oromendia and Amon, 2014; Stingele
et al., 2012). Gene copy number changes due to aneuploidy can
affect the number of proteins expressed, their functions and the
protein quality-control and repair machinery of the cell (Sheltzer
et al., 2011; Oromendia et al., 2012; Thorburn et al., 2013; Yurov
et al., 2014).
Thus, in DS, the extra chromosome can alter proteostasis
(Lockstone et al., 2007). Trisomy may also affect the 3D
nuclear architecture of the genome resulting in changes in gene
interactions and gene expression that may impact proteostasis
regulation (Vermunt et al., 2019).
Regarding protein synthesis, only a few studies have analyzed
the ribosome biogenesis machinery in DS. Demirtas (2009), using
a classic silver staining procedure to study the arrangement of
the nucleolar organizer regions (NORs), found that cells from DS
infants presented an increased number of AgNOR dots. Because
ribosome biogenesis is a highly energy-consuming process, these
authors suggest that this response to trisomy 21 might result
in unnecessary rRNA and ribosomal protein synthesis, which
leads to a waste in energy. Also, reduced expression of specific
transcription, splicing, and translation factors has been found
in cortices of fetuses with DS (Freidl et al., 2001), suggesting a
deranged protein synthesis in them.
Moreover, in DS, both intracellular degradative systems,
UPS and autophagy, seem to be affected. Chronic exposure to
oxidative stress, as occurs in the DS brain, also causes protein
oxidation of members of the proteostasis network, resulting
in accumulation of unfolded/damaged protein aggregates
and dysfunction of intracellular degradative system, such
as autophagy and the ubiquitin-proteasome systems (UPS),
contributing to neurodegeneration (Di Domenico et al., 2013;
Hetz and Mollereau, 2014). In the hippocampus of Ts65Dn
mice altered autophagy, due to reduction of autophagosome
formation, has been found (Tramutola et al., 2016). In
DS human fibroblasts and in the brain of two segmental
trisomy models of DS, the Dp16 and Dp17 mice, increased
ubiquitination, and disrupted proteasome activity has been
reported (Aivazidis et al., 2017). Finally, in the cerebellum of
the Ts65Dn mouse, a dysfunction of the UPS, due to reduced
proteasome activity and a parallel increase of ubiquitinated
proteins, has been implicated in the degeneration of Purkinje
cells (Necchi et al., 2011). Consequently, ubiquitinated or
polyubiquitinated proteins are not degraded at a normal rate
and are stored in the nuclei of cerebellar neurons of this model
(Necchi et al., 2011).
Besides, disruption in the proteostasis network could
contribute to the accumulation of protein aggregates, such
as amyloid deposits and NFTs (Di Domenico et al., 2013).
Alterations of the proteostasis network are present in individuals
with DS years before the age-related cognitive decline, and
AD-associated dementia is detected.
In summary, DS is characterized by early senescence that
continues throughout the lifespan of the individual and is very
likely aggravated by the appearance of AD neuropathology.
CELLULAR SENESCENCE IN PARKINSON
DISEASE
PD is a progressive neurodegenerative disorder characterized
by the loss of dopaminergic neurons in the substantia nigra,
the presence of cytoplasmic protein aggregates, known as Lewy
bodies, that contain a variety of proteins, including ubiquitin
and α-synuclein (Nussbaum and Ellis, 2003; Thomas and Beal,
2011). These pathological features result in an impairment of
motor control, including difficulty to initiate movements, loss of
balance, rigidity, and tremor, and cognitive deterioration (Poewe
et al., 2017). The most important risk factors for the development
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of PD are aging, a genetic predisposition and exposure to toxins
(Chinta et al., 2013).
Similarly to AD and DS, PD neuropathology is aggravated
by neuroinflammation mitochondrial dysfunction, α-synuclein
accumulation, oxidative stress, and cellular senescence (Poewe
et al., 2017).
There is widespread evidence that cellular senescence plays
an essential role in the pathogenesis of PD. Patients with PD
present enhanced levels of SA-β-gal in their CSF (van Dijk et al.,
2013) and in their brain tissue (Chinta et al., 2018). Higher
numbers of senescent astrocytes are also present in the substantia
nigra of patients with PD (Chinta et al., 2018). Besides, paraquat,
a herbicide that has been proposed to be implicated in the
appearance of some types of PD, induces senescence in human
astrocytes (Chinta et al., 2018).
Neuroinflammation
Similarly to AD and DS, inflammation is prominent in PD
(Chinta et al., 2018). Activation of microglia is thought to
be one of the main determinants of dopaminergic loss in the
substantia nigra (McGeer et al., 1988), hippocampus, cingulate
and temporal cortex (Imamura et al., 2003). α-synuclein
aggregation activates microglial cells in PD (Zhang et al., 2005).
The result of microglia activation is in the increased levels of
the pro-inflammatory mediators IL-1, IL-6, TNFγ and TNF-α in
the CSF, serum, and dopaminergic regions of the striatum from
patients with PD (Mogi et al., 1994a,b; Blum-Degen et al., 1995;
McCoy et al., 2006; Mount et al., 2007; Brodacki et al., 2008;
Scalzo et al., 2010; Lindqvist et al., 2012; Dursun et al., 2015).
The high presence of senescent cells and aged astrocytes in
PDs brains suggests that senescence-induced neuroinflammation
might be an important mechanism for PD neurodegeneration
and a potential therapeutic target for this disease.
Oxidative Stress and Mitochondrial
Dysfunction
Oxidative stress plays an essential role in the etiology and
progression of PD (Trist et al., 2019). Even in the early stages
of the disease, before a significant loss of dopaminergic neurons,
PD patients present elevated oxidative stress (Ferrer et al.,
2011). Thus, oxidative stress could be partially responsible for
neurodegeneration, in addition to been enhanced as a result of
the neuronal loss. As demonstrated in AD and DS, it seems that
positive feedback is produced between both insults that probably
aggravates the disease.
Mitochondrial dysfunction also plays a vital role in PD
etiopathology. In familial PD, different mutations in the genes
associated with pathways of mitochondrial dysfunction have
been demonstrated, and some of these pathways are also altered
in sporadic PD (Park et al., 2018). The production of ROS
during ATP synthesis is higher in dopaminergic neurons of
the substantia nigra. Due to their size and complexity, they
need more elevated amounts of ATP to maintain resting
membrane potential, propagate action potentials, and enable
synaptic transmission (Pissadaki and Bolam, 2013).
These alterations in mitochondrial function and oxidative
stress are likely to be a result of senescence.
DNA Damage and Repair
DNA damage and repair have been proposed as important
actors altering the function of the dopaminergic system in
PD (Sepe et al., 2016). Telomere shortening plays a causal
role in cellular aging (Hastie et al., 1990), and it has been
proposed as a potential contributor in the pathogenesis of PD
(Anitha et al., 2019).
The studies of telomere length in PD patients had provided
contradictory results. Some of them provide support for shorter
telomere length in different cell types or tissues (Tomac and
Hoffer, 2001; Guan et al., 2008; Koliada et al., 2014) while others
do not find evidence of this alteration in PD (Guan et al., 2008;
Wang et al., 2008; Eerola et al., 2010; Watfa et al., 2011; Maeda
et al., 2012; Degerman et al., 2014; Eitan et al., 2014; Forero et al.,
2016). A meta-analysis of all these studies concluded that PD
patients do not present changes in telomere length (Forero et al.,
2016). Thus, new studies are necessary to clarify the putative role
of replicative senescence and telomere shortening in different
brain regions and cell types in PD.
However, it has been demonstrated that PD is characterized
by genetic instability due to gene mutations, altered gene
expression, or regulation. The expression of some genes
implicated in the cell cycle, such as p16INK4a (Chinta et al., 2018)
and pRb (Ihara et al., 2012), are upregulated in PD brains. This
enhanced genetic expression is likely to produce alterations in
the cell cycle in this disorder.
Furthermore, alterations in epigenetic modulation seem
to play an important role in the etiopathology of PD. The
brains of these patients present changes in DNA methylation,
post-translational modifications of histones and of microRNAs
that regulate pathways involved in the pathophysiology
of PD (Armstrong et al., 2019; Prasad and Jho, 2019;
Renani et al., 2019).
However, the role of the alterations of DNA methylation
in the pathological hallmarks of this disease, including cellular
senescence, is still unclear.
Proteostasis
Another characteristic that PD shares with other
neurodegenerative diseases is altered proteostasis. In PD,
there is an accumulation of misfolded proteins in the brain
(Martinez et al., 2019). All patients with PD present insoluble
α-synuclein fibrils, which damage neurons, and are associated
with intracellular Lewy bodies (Melki, 2015). Alterations in the
proteostasis network seem to play a prominent role in the protein
aggregation found in PD, mainly due to changes in the function
of the ER, the organelle involved in protein folding and quality
control. ER stress produces the UPR to try to restore proteostasis.
In this disease, the increase in senescent cells is thought to be
directly associated with the enhanced aggregation of α-synuclein
(Chinta et al., 2018).
It has been proposed that mitochondrial dysfunction and
oxidative stress could be partially responsible for this α- synuclein
accumulation (Dias et al., 2013; Rocha et al., 2018).
Finally, the autophagic/lysosomal dysfunction also plays
an essential role in the pathogenesis of the disease, since
different genetic mutations that produce defects in these
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pathways are found in PD patients (Rivero-Ríos et al., 2016;
Pitcairn et al., 2018).
In summary, cellular senescence is also a pathological
event of crucial importance in PD, and shares with other
neurodegenerative diseases many of the factors that trigger
it and aggravate the neuropathology (i.e., oxidative stress,
mitochondrial dysfunction, altered proteostasis, among others).
CONCLUDING REMARKS
Senescent cells accumulate with aging and in neurodegenerative
pathologies, and there is extensive evidence that they might
be implicated in the etiopathology of these diseases. Here, we
reviewed the data that demonstrate that cellular senescence
is a common pathological feature of PD, AD, and DS.
These three diseases also share some of the mechanisms
that promote senescence and that allow this permanent state
of cell arrest to induce or aggravate neurodegeneration.
Furthermore, extensive senescence has also been found in other
neurodegenerative diseases such as Huntington Disease, Multiple
Sclerosis, and Rett syndrome. Thus, senescence seems to be a
common mechanism for neurodegeneration that needs to be
further investigated.
At present, there are no efficient neuroprotective treatments
that can prevent or delay the progression of the disease for
AD in individuals with or without DS or for PD. Thus, new
neuroprotective therapeutic approaches are needed.
Because of the central role of cellular senescence in the
etiopathology of different neurodegenerative diseases, therapies
that reduce senescence could be a promising approach to prevent
the loss of cells and the alteration of their function. These
therapies have been more extensively investigated in the case of
AD (He et al., 2013; Kirkland and Tchkonia, 2017).
Several therapeutic strategies, known as senotherapies, to
selective eliminate tissue-specific senescent cells, have been
developed (Childs et al., 2017; Kritsilis et al., 2018; Kim and
Kim, 2019). However, almost none have been tested in models
of different neurodegenerative diseases, except AD. Clearance of
senescent cells extended lifespan in normal mice (Baker et al.,
2016) and in a progeroid mouse model (Baker et al., 2011).
Finally, a recent work has demonstrated that pharmacological
elimination of senescent astrocytes and microglia cells using a
senolytic compound (ABT263) attenuates tau phosphorylation,
modulates tau aggregation, prevents the upregulation of
senescence-associated genes in the cortex and hippocampus and
improves short-term memory in a transgenic mouse model that
overexpresses human tau (Kirkland and Tchkonia, 2017; Bussian
et al., 2018). Thus, senotherapeutic agents may serve as powerful
tools to prevent neurodegenerative diseases.
Importantly, in many of these disorders, senescence is an early
event that appears years before other signs of neurodegeneration
and in the case of DS, even at embryonic stages, providing a broad
therapeutic window to prevent or delay some of the pathological
processes associated.
Finally, many of the mechanisms implicated in the
onset of senescence and that also appear years earlier than
neurodegeneration (i.e., oxidative stress, mitochondrial damage,
neuroinflammation, DNA damage, altered proteostasis), are
also a result of senescence, therefore aggravating the disease
(Figure 1). Thus, therapies targeting these earlier events
could exert a double benefit preventing the onset of the
neurodegenerative disease or delaying its progress.
AUTHOR CONTRIBUTIONS
CM-C and NR wrote and edited the manuscript.
FUNDING
This study was supported by Fundación Tatiana Pérez de
Guzmán el Bueno, IDIVAL, the grant reference (NVAL 19/23)
and the Spanish Ministry of Economy and Competitiveness
(Ministerio de Economía y Competitividad; PSI-2016-76194-R,
AEI/FEDER, EU).
REFERENCES
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P.,
et al. (2013). A complex secretory program orchestrated by the
inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990.
doi: 10.1038/ncb2784
Adorno, M., Sikandar, S., Mitra, S. S., Kuo, A., Nicolis Di Robilant, B., Haro-
Acosta, V., et al. (2013). Usp16 contributes to somatic stem-cell defects in
Down’s syndrome. Nature 501, 380–384. doi: 10.1038/nature12530
Agarwal, S. S., Blumberg, B. S., Gerstley, B. J., London, W. T., Sutnick, A. I.,
and Loeb, L. A. (1970). DNA polymerase activity as an index of lymphocyte
stimulation: studies in Down’s syndrome. J. Clin. Invest. 49, 161–169.
doi: 10.1172/jci106215
Ahmed, A. A., Smoczer, C., Pace, B., Patterson, D., and Cress Cabelof, D. (2018).
Loss of DNA polymerase β induces cellular senescence. Environ. Mol. Mutagen.
59, 603–612. doi: 10.1002/em.22206
Aivazidis, S., Coughlan, C. M., Rauniyar, A. K., Jiang, H., Liggett, L. A.,
Maclean, K. N., et al. (2017). The burden of trisomy 21 disrupts the proteostasis
network in Down syndrome. PLoS One 12:e0176307. doi: 10.1371/journal.
pone.0176307
Allsopp, R. C., Vaziri, H., Pattersont, C., Goldsteint, S., Younglai, E. V.,
Futcher, A. B., et al. (1992). Telomere length predicts replicative capacity
of human fibroblasts. Proc. Natl. Acad. Sci. U S A 89, 10114–10118.
doi: 10.1073/pnas.89.21.10114
Al-Mashhadi, S., Simpson, J. E., Heath, P. R., Dickman, M., Forster, G.,
Matthews, F. E., et al. (2015). Oxidative glial cell damage associated with
white matter lesions in the aging human brain. Brain Pathol. 25, 565–574.
doi: 10.1111/bpa.12216
Amiel, A., Fejgin, M. D., Liberman, M., Sharon, Y., Kidron, D., and
Biron-Shental, T. (2013). Senescence in amniocytes and placentas from
trisomy 21 pregnancies. J. Matern. Fetal Neonatal Med. 26, 1086–1089.
doi: 10.3109/14767058.2013.768982
Anitha, A., Thanseem, I., Vasu, M. M., Viswambharan, V., and Poovathinal, S. A.
(2019). Telomeres in neurological disorders. Adv. Clin. Chem. 90, 81–132.
doi: 10.1016/bs.acc.2019.01.003
Arendt, T., Rödel, L., Gärtner, U., and Holzer, M. (1996). Expression of the
cyclin-dependent kinase inhibitor p16 in Alzheimer’s disease. Neuroreport 7,
3047–3049. doi: 10.1097/00001756-199611250-00050
Armstrong, M. J., Jin, Y., Allen, E. G., and Jin, P. (2019). Diverse and dynamic
DNA modifications in brain and diseases. Hum. Mol. Genet. 28, R241–R253.
doi: 10.1093/hmg/ddz179
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Siebe, C. J., Zhong, J., et al.
(2016). Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.
Nature 530, 184–189. doi: 10.1038/nature16932
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 February 2020 | Volume 14 | Article 16
Martínez-Cué and Rueda Senescence in Neurodegenerative Diseases
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de
Sluis, B., et al. (2011). Clearance of p16Ink4a-positive senescent cells delays
ageing-associated disorders. Nature 479, 232–236. doi: 10.1038/nature10600
Barbouti, A., Evangelou, K., Pateras, I. S., Papoudou-Bai, A., Patereli, A.,
Stefanaki, K., et al. (2019). In situ evidence of cellular senescence in Thymic
Epithelial Cells (TECs) during human thymic involution. Mech. Ageing Dev.
177, 88–90. doi: 10.1016/j.mad.2018.02.005
Barger, S. W., and Harmon, A. D. (1997). Microglial activation by alzhelmer
amyloid precursor protein and modulation by apolipoprotein E. Nature 388,
878–881. doi: 10.1038/42257
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., et al.
(1991). Interleukin-6 and α-2-macroglobulin indicate an acute-phase state
in Alzheimer’s disease cortices. FEBS Lett. 285, 111–114. doi: 10.1016/0014-
5793(91)80737-n
Bernatdotte, A., Mikhelson, V. M. K., and Spivak, I. M. (2016). Markers of cellular
senescence. Telomere shortening as a marker of cellular senescence. Aging 8,
1–9. doi: 10.18632/aging.100871
Berson, A., Nativio, R., Berger, S. L., and Bonini, N. M. (2018). Epigenetic
regulation in neurodegenerative diseases. Trends Neurosci. 41, 587–598.
doi: 10.1016/j.tins.2018.05.005
Bhat, R., Crowe, E. P., Bitto, A., Moh, M., Katsetos, C. D., Garcia, F. U., et al.
(2012). Astrocyte senescence as a component of Alzheimer’s disease. PLoS One
7:e45069. doi: 10.1371/journal.pone.0045069
Birch, J., Anderson, R. K., Correia-Melo, C., Jurk, D., Hewitt, G., Marques, F. M.,
et al. (2015). DNA damage response at telomeres contributes to lung aging and
chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol.
309, L1124–L1137. doi: 10.1152/ajplung.00293.2015
Biron-Shental, T., Liberman, M., Sharvit, M., Sukenik-Halevy, R., and Amiel, A.
(2015). Amniocytes from aneuploidy embryos have enhanced random
aneuploidy and signs of senescence—can these findings be related to medical
problems? Gene 562, 232–235. doi: 10.1016/j.gene.2015.02.075
Bischoff, C., Petersen, H., Graakjaer, J., Andersen-Ranberg, K., Vaupel, J., Bohr, V.,
et al. (2006). No association between telomere length and survival among
the elderly and oldest old. Epidemiology 17, 190–194. doi: 10.1097/01.ede.
0000199436.55248.10
Bitto, A., Sell, C., Crowe, E., Lorenzini, A., Malaguti, M., Hrelia, S., et al. (2010).
Stress-induced senescence in human and rodent astrocytes. Exp. Cell Res. 316,
2961–2968. doi: 10.1016/j.yexcr.2010.06.021
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., and Andreasson, U.
(2011). Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of
metalloproteinases in combination with subcortical and cortical biomarkers
in vascular dementia and Alzheimer’s disease. J. Alzheimers Dis. 27, 665–676.
doi: 10.3233/jad-2011-110566
Blackburn, E. H. (1991). Structure and function of telomeres. Nature 350, 569–573.
doi: 10.1038/350569a0
Blasco, M. A., Lee, H. W., Hande, M. P., Samper, E., Lansdorp, P. M.,
DePinho, R. A., et al. (1997). Telomere shortening and tumor formation
by mouse cells lacking telomerase RNA. Cell 91, 25–34. doi: 10.1016/s0092-
8674(01)80006-4
Blum-Degen, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P.
(1995). Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid
of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci. Lett. 202,
17–20. doi: 10.1016/0304-3940(95)12192-7
Blurton-Jones, M., and Laferla, F. M. (2006). Pathways by which Aβ facilitates tau
pathology. Curr. Alzheimer Res. 3, 437–448. doi: 10.2174/156720506779025242
Boccardi, V., Pelini, L., Ercolani, S., Ruggiero, C., and Mecocci, P. (2015). From
cellular senescence to Alzheimer’s disease: the role of telomere shortening.
Ageing Res. Rev. 22, 1–8. doi: 10.1016/j.arr.2015.04.003
Bradley-Whitman, M. A., and Lovell, M. A. (2013). Epigenetic changes in
the progression of Alzheimer’s disease. Mech. Ageing Dev. 134, 486–495.
doi: 10.1016/j.mad.2013.08.005
Brand, M. D. (2014). The role of mitochondria in longevity and healthspan.
Longev. Healthspan 3:7. doi: 10.1186/2046-2395-3-7
Brodacki, B., Staszewski, J., Toczyowska, B., Kozowska, E., Drela, N.,
Chalimoniuk, M., et al. (2008). Serum interleukin (IL-2, IL-10, IL-6, IL-4),
TNF, and INF concentrations are elevated in patients with atypical and
idiopathic parkinsonism. Neurosci. Lett. 441, 158–162. doi: 10.1016/j.neulet.
2008.06.040
Brosh, R. M., and Bohr, V. A. (2007). Human premature aging, DNA repair and
RecQ helicases. Nucleic Acids Res. 35, 7527–7544. doi: 10.1093/nar/gkm1008
Busciglio, J., Pelsman, A., Helguera, P., Ashur-Fabian, O., Pinhasov, A.,
Brenneman, D. E., et al. (2007). NAP and ADNF-9 protect normal and Down’s
syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharm.
Des. 13, 1091–1098. doi: 10.2174/138161207780618957
Busciglio, J., and Yankner, B. A. (1995). Apoptosis and increased generation of
reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378,
776–779. doi: 10.1038/378776a0
Bussian, T. J., Aziz, A., Meyer, C. F., Swenson, B. L., van Deursen, J. M., and
Baker, D. J. (2018). Clearance of senescent glial cells prevents tau-dependent
pathology and cognitive decline. Nature 562, 578–582. doi: 10.1038/s41586-
018-0543-y
Cabelof, D. C. (2007). Aging and base excision repair: in need of a comprehensive
approach. DNA Repair 6, 1399–1402. doi: 10.1016/j.dnarep.2007.
06.006
Cabelof, D. C., Guo, Z., Raffoul, J. J., Sobol, R. W., Wilson, S. H., Richardson, A.,
et al. (2003). Base excision repair deficiency caused by polymerase β
haploinsufficiency: accelerated DNA damage and increased mutational
response to carcinogens. Cancer Res. 63, 5799–5807.
Cabelof, D. C., Patel, H. V., Chen, Q., van Remmen, H., Matherly, L. H.,
Ge, Y., et al. (2009). Mutational spectrum at GATA1 provides insights into
mutagenesis and leukemogenesis in Down syndrome. Blood 114, 2753–2763.
doi: 10.1182/blood-2008-11-190330
Cabelof, D. C., Raffoul, J. J., Yanamadala, S., Ganir, C., Guo, Z., and Heydari, A. R.
(2002). Attenuation of DNA polymerase β-dependent base excision repair and
increased DMS-induced mutagenicity in aged mice. Mutat. Res. 500, 135–145.
doi: 10.1016/s0027-5107(02)00003-9
Cacabelos, R., Alvarez, X. A., Fernández-Novoa, L., Franco, A., Mangues, R.,
Pellicer, A., et al. (1994). Brain interleukin-1β in Alzheimer’s disease and
vascular dementia. Methods Find. Exp. Clin. Pharmacol. 16, 141–151.
Cadonic, C., Sabbir, M. G., and Albensi, B. C. (2016). Mechanisms of
mitochondrial dysfunction in Alzheimer’s disease. Mol. Neurobiol. 53,
6078–6090. doi: 10.1007/s12035-015-9515-5
Cai, Z., Yan, L.-J., and Ratka, A. (2013). Telomere shortening and Alzheimer’s
disease. Neuromolecular. Med. 15, 25–48. doi: 10.1007/s12017-012-8207-9
Caldeira, C., Cunha, C., Vaz, A. R., Falcão, A. S., Barateiro, A., Seixas, E., et al.
(2017). Key aging-associated alterations in primary microglia response to
β-amyloid stimulation. Front. Aging Neurosci. 9:277. doi: 10.3389/fnagi.2017.
00277
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D.,
Oldstone, M. B., et al. (1993). Neurologic disease induced in transgenic mice
by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U S A 90,
10061–10065. doi: 10.1073/pnas.90.21.10061
Casanova, M. F., Walker, L. C., Whitehouse, P. J., and Price, D. L. (1985).
Abnormalities of the nucleus basalis in Down’s syndrome. Ann. Neurol. 18,
310–313. doi: 10.1002/ana.410180306
Cencioni, C., Spallotta, F., Martelli, F., Valente, S., Mai, A., Zeiher, A., et al. (2013).
Oxidative stress and epigenetic regulation in ageing and age-related diseases.
Int. J. Mol. Sci. 14, 17643–17663. doi: 10.3390/ijms140917643
Cenini, G., Dowling, A. L., Beckett, T. L., Barone, E., Mancuso, C., Murphy, M. P.,
et al. (2012). Association between frontal cortex oxidative damage and
β-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 1822,
130–138. doi: 10.1016/j.bbadis.2011.10.001
Chan, S. R. W. L., and Blackburn, E. H. (2004). Telomeres and telomerase.
Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 109–122. doi: 10.1098/rstb.
2003.1370
Chen, Y., McMillan-Ward, E., Kong, J., Israels, S. J., and Gibson, S. B. (2007).
Mitochondrial electron–transport–chain inhibitors of complexes I and II
induce autophagic cell death mediated by reactive oxygen species. J. Cell Sci.
120, 4155–4166. doi: 10.1242/jcs.011163
Chen, H., Ruiz, P. D., McKimpson, W. M., Novikov, L., Kitsis, R. N., and
Gamble, M. J. (2015). MacroH2A1 and ATM play opposing roles in paracrine
senescence and the senescence-associated secretory phenotype. Mol. Cell 59,
719–731. doi: 10.1016/j.molcel.2015.07.011
Childs, B. G., Durik, M., Baker, D. J., and van Deursen, J. M. (2015). Cellular
senescence in aging and age–related disease: from mechanisms to therapy. Nat.
Med. 21, 1424–1435. doi: 10.1038/nm.4000
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 February 2020 | Volume 14 | Article 16
Martínez-Cué and Rueda Senescence in Neurodegenerative Diseases
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R. M., Marquess, D.,
Dananberg, J., et al. (2017). Senescent cells: an emerging target for diseases of
ageing. Nat. Rev. Drug Discov. 16, 718–735. doi: 10.1038/nrd.2017.116
Chinta, S. J., Lieu, C. A., Demaria, M., Laberge, R. M., Campisi, J., and
Andersen, J. K. (2013). Environmental stress, ageing and glial cell senescence:
a novel mechanistic link to Parkinson’s disease? J. Intern. Med. 273, 429–436.
doi: 10.1111/joim.12029
Chinta, S. J., Woods, G., Demaria, M., Rane, A., Zou, Y., Mcquade, A., et al. (2018).
Cellular senescence is induced by the environmental neurotoxin paraquat and
contributes to neuropathology linked to Parkinson’s disease. Cell Rep. 22,
930–940. doi: 10.1016/j.celrep.2017.12.092
Chong, Y. (1997). Effect of a carboxy-terminal fragment of the Alzheimer’s
amyloid precursor protein on expression of proinflammatory cytokines in rat
glial cells. Life Sci. 61, 2323–2333. doi: 10.1016/s0024-3205(97)00936-3
Chow, H. M., and Herrup, K. (2015). Genomic integrity and the ageing brain. Nat.
Rev. Neurosci. 16, 672–684. doi: 10.1038/nrn4020
Chung, K. M., Hernández, N., Sproul, A., and Yu, W. H. (2018). Alzheimer’s
disease and the autophagic-lysosomal system. Neurosci. Lett. 697, 49–58.
doi: 10.1016/j.neulet.2018.05.017
Cipriani, S., Ferrer, I., Aronica, E., Kovacs, G. G., Verney, C., Nardelli, J., et al.
(2018). Hippocampal radial glial subtypes and their neurogenic potential in
human fetuses and healthy and Alzheimer’s disease adults. Cereb. Cortex 28,
2458–2478. doi: 10.1093/cercor/bhy096
Cleaver, J. E., Kaufmann, W. K., Kapp, L. N., and Park, S. D. (1983). Replicon size
and excision repair as factors in the inhibition and recovery of DNA synthesis
from ultraviolet damage, Biochim. Biochim. Biophys. Acta 739, 207–215.
doi: 10.1016/0167-4781(83)90031-3
Combrinck, M., Perry, V., and Cunningham, C. (2002). Peripheral infection
evokes exaggerated sickness behaviour in pre-clinical murine prion disease.
Neuroscience 112, 7–11. doi: 10.1016/s0306-4522(02)00030-1
Conde, J. R., and Streit, W. J. (2006). Microglia in the aging brain. J. Neuropathol.
Exp. Neurol. 65, 199–203. doi: 10.1097/01.jnen.0000202887.22082.63
Contestabile, A., Fila, T., Bartesaghi, R., and Ciani, E. (2009a). Cell cycle elongation
impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse,
an animal model for Down syndrome. Brain Pathol. 19, 224–237. doi: 10.1111/j.
1750-3639.2008.00168.x
Contestabile, A., Fila, T., Cappellini, A., Bartesaghi, R., and Ciani, E. (2009b).
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a
model for Down syndrome. Cell Prolif. 42, 171–181. doi: 10.1111/j.1365-2184.
2009.00587.x
Contestabile, A., Fila, T., Ceccarelli, C., Bonasoni, P., Bonapace, L., Santini, D.,
et al. (2007). Cell cycle alteration and decreased cell proliferation in the
hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses
with Down syndrome and in Ts65Dn mice. Hippocampus 17, 665–678.
doi: 10.1002/hipo.20308
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., and Campisi, J. (2010). The senescence-
associated secretory phenotype: the dark side of tumor suppression. Annu. Rev.
Pathol. 5, 99–118. doi: 10.1146/annurev-pathol-121808-102144
Cormenier, J., Martin, N., Deslé, J., Salazar-Cardozo, C., Pourtier, A., Abbadie, C.,
et al. (2018). The ATF6 arm of the Unfolded Protein Response mediates
replicative senescence in human fibroblasts through a COX2/prostaglandin E2
intracrine pathway. Mech. Ageing Dev. 170, 82–91. doi: 10.1016/j.mad.2017.
08.003
Corrales, A., Martínez, P., García, S., Vidal, V., García, E., Flórez, J., et al. (2013).
Long-term oral administration of melatonin improves spatial learning and
memory and protects against cholinergic degeneration in middle-aged Ts65Dn
mice, a model of Down syndrome. J. Pineal Res. 54, 346–358. doi: 10.1111/jpi.
12037
Corrales, A., Vidal, R., García, S., Vidal, V., Martínez, P., García, E.,
et al. (2014). Chronic melatonin treatment rescues electrophysiological and
neuromorphological deficits in a mouse model of Down syndrome. J. Pineal
Res. 56, 51–61. doi: 10.1111/jpi.12097
Correia-Melo, C., and Passos, J. F. (2015). Mitochondria: are they causal players
in cellular senescence? Biochim. Biophys. Acta 1847, 1373–1379. doi: 10.1016/j.
bbabio.2015.05.017
Cristofalo, V. J., Lorenzini, A., Allen, R. G., Torres, C., and Tresini, M. (2004).
Replicative senescence: a critical review. Mech. Ageing Dev. 125, 827–848.
doi: 10.1016/j.mad.2004.07.010
Cunningham, C., Wilcockson, D., Campion, S., Lunnon, K., and Perry, V. (2005).
Central and systemic endotoxin challenges exacerbate the local inflammatory
response and increase neuronal death during chronic neurodegeneration.
J. Neurosci. 25, 9275–9284. doi: 10.1523/JNEUROSCI.2614-
05.2005
d’Adda di Fagagna, F., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., Von
Zglinicki, T., et al. (2003). A DNA damage checkpoint response in telomere-
initiated senescence. Nature 426, 194–198. doi: 10.1038/nature02118
de Arruda Cardoso Smith, M., Borsatto-Galera, B., Feller, R. I., Gonçalves, A.,
Oyama, R. S., Segato, R., et al. (2004). Telomeres on chromosome 21 and aging
in lymphocytes and gingival fibroblasts from individuals with Down syndrome.
J. Oral Sci. 46, 171–177. doi: 10.2334/josnusd.46.171
De Haan, J. B., Cristiano, F., Iannello, R., Bladier, C., Kelner, M. J., and
Kola, I. (1996). Elevation in the ratio of Cu/Zn-superoxide dismutase to
glutathione peroxidase activity induces features of cellular senescence and
this effect is mediated by hydrogen peroxide. Hum. Mol. Genet. 5, 283–292.
doi: 10.1093/hmg/5.2.283
de la Monte, S. M., Sohn, Y. K., and Wands, J. R. (1997). Correlates of p53- and Fas
(CD95)-mediated apoptosis in Alzheimer’s disease. J. Neurol. Sci. 152, 73–83.
doi: 10.1016/s0022-510x(97)00131-7
de Lange, T. (2002). Protection of mammalian telomeres. Oncogene 21, 532–540.
doi: 10.1038/sj.onc.1205080
De Stefano, N., Stromillo, M. L., Giorgio, A., Bartolozzi, M. L., Battaglini, M.,
Baldini, M., et al. (2016). Establishing pathological cut-offs of brain atrophy
rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 87, 93–99.
doi: 10.1136/jnnp-2014-309903
Degerman, S., Domellof, M., Landfors, M., Linder, J., Lundin, M., Haraldsson, S.,
et al. (2014). Long leukocyte telomere length at diagnosis is a risk factor
for dementia progression in idiopathic parkinsonism. PLoS One 9:e113387.
doi: 10.1371/journal.pone.0113387
Demirtas, H. (2009). AgNOR status in Down’s syndrome infants and a plausible
phenotype formation hypothesis. Micron 40, 511–518. doi: 10.1016/j.micron.
2009.02.014
Di Domenico, F., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E.,
et al. (2013). Impairment of proteostasis network in Down syndrome
prior to the development of Alzheimer’s disease neuropathology: redox
proteomics analysis of human brain. Biochim. Biophys. Acta 1832, 1249–1259.
doi: 10.1016/j.bbadis.2013.04.013
Dias, V., Junn, E., and Mouradian, M. M. (2013). The role of oxidative
stress in Parkinson’s disease. J. Parkinsons Dis. 3, 461–491. doi: 10.3233/
JPD-130230
Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., and Brosnan, C. (1993).
Microglia and cytokines in neurological disease, with special reference to AIDS
and Alzheimer’s disease. Glia 7, 75–83. doi: 10.1002/glia.440070113
Di Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A.,
et al. (2015). Bach1 overexpression in Down syndrome correlates with the
alteration of the HO-1/BVR-A system: insights for transition to Alzheimer
disease. J. Alzheimers Dis. 44, 1107–1120. doi: 10.3233/Jad-141254
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., et al.
(2013). Synthetic lethal metabolic targeting of cellular senescence in cancer
therapy. Nature 501, 421–425. doi: 10.1038/nature12437
Dröge, W., and Schipper, H. (2007). Oxidative stress and aberrant signaling in
aging and cognitive decline. Aging Cell 6, 361–370. doi: 10.1111/j.1474-9726.
2007.00294.x
Druelle, C., Drullion, C., Deslé, J., Martin, N., Saas, L., Cormenier, J., et al. (2016).
ATF6α regulates morphological changes associated with senescence in human
fibroblasts. Oncotarget 7, 67699–67715. doi: 10.18632/oncotarget.11505
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